|Bid||82.00 x 900|
|Ask||92.47 x 900|
|Day's Range||88.50 - 90.44|
|52 Week Range||78.95 - 116.49|
|Beta (3Y Monthly)||0.95|
|PE Ratio (TTM)||16.87|
|Earnings Date||Apr 23, 2019|
|Forward Dividend & Yield||2.12 (2.37%)|
|1y Target Est||94.59|
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Quest Diagnostics Inc NYSE:DGXView full report here! Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for DGX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold DGX had net inflows of $3.73 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. DGX credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
SECAUCUS, N.J., March 7, 2019 /PRNewswire/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, announced today the pricing of a public offering of $500 million aggregate principal amount of its 4.200% senior notes due 2029 under the Quest Diagnostics' shelf registration statement. Quest Diagnostics expects to receive the net offering proceeds upon closing on March 12, 2019, subject to customary closing conditions. The company intends to use the net proceeds from the offering to repay outstanding indebtedness, which includes the $300 million aggregate principal amount of its senior notes due April 2019, and indebtedness under its secured receivables credit facility, and for general corporate purposes. This press release shall not constitute an offer to sell or a solicitation of an offer to purchase any of these securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.
Moody's Investors Service ("Moody's") assigned a Baa2 rating to the proposed offering of senior unsecured notes of Quest Diagnostics Incorporated ("Quest"). There are no changes to Moody's existing ratings of Quest including the Baa2 senior unsecured long-term rating. Further, Quest has a long track record of maintaining modest financial leverage and generating stable cash flows, which Moody's expects will continue.
SECAUCUS, N.J., March 7, 2019 /PRNewswire/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Barclays Global Healthcare Conference in Miami. Mark Guinan, Executive Vice President and CFO will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.
Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. And the truth is, you can make significantRead More...
SECAUCUS, N.J. , March 1, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly ...
SECAUCUS , N.J. and ORANGEBURG, S.C. , Feb. 27, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Regional Medical Center (RMC) of ...
Quest Diagnostics' (DGX) progress in prescription drug monitoring, QuantiFERON and non-invasive prenatal screening are part of its recent major developments.
NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Quest Diagnostics Inc provides diagnostic testing, information, and services, providing insights that enable patients and physicians to make healthcare decisions. The dividend yield of Quest Diagnostics Inc stocks is 2.30%. Quest Diagnostics Inc had annual average EBITDA growth of 3.00% over the past ten years.
SECAUCUS, N.J. and WARNER ROBINS, Ga., Feb. 20, 2019 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Houston Healthcare are teaming up to enhance the quality and value of diagnostic services to patients and their doctors through a new partnership agreement under which Quest will provide full laboratory management services for Houston Medical Center and Perry Hospital.
SECAUCUS, N.J., Feb. 19, 2019 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Denise M. Morrison to serve as a director, effective February 18, 2019. Including Ms. Morrison, the company's Board has 11 members. Ms. Morrison served as President and Chief Executive Officer of Campbell Soup Company from 2011 to 2018. "In addition to her broad management experiences, Denise has a deep understanding of the consumer market and will bring a helpful new perspective as Quest pursues its strategy to be the most consumer-oriented diagnostic information services provider," said Steve Rusckowski, Chairman, CEO and President.
SECAUCUS, N.J., Feb. 18, 2019 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, announced today that Gabrielle Wolfson, a veteran information technology business leader, has been named Senior Vice President and Chief Information and Digital Officer. Ms. Wolfson is responsible for leading information technology, data informatics and digital solutions for Quest Diagnostics. "Gabrielle is a dynamic business and technology leader with a proven record of harnessing technology and data to create strong businesses and engaged, loyal customers," said Mr. Rusckowski.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! It is not uncommon to see companies perform well inRead More...
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 0.00% and -2.42%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Secaucus, New Jersey-based company said it had net income of 92 cents. Earnings, adjusted for one-time gains and costs, came to $1.36 per share. The results met Wall Street expectations. ...
- Fourth quarter revenues of $1.84 billion , down 1.4% versus 2017 - Fourth quarter diluted EPS of $0.92 on a reported basis, down 49.5% from 2017 which included a tax benefit recorded as a result of the ...
is expected to report earnings of $1.37 a share on sales of $1.9 billion before the market opens Feb. 14, based on a FactSet survey of 17 analysts. The stock has fallen 6.3% since the company last reported earnings on Oct. 23. Quest Diagnostics is currently trading at a price-to-forward-earnings ratio of 13.6 based on the 12-month estimates of 19 analysts surveyed by FactSet.